TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
20/08/26	$2.970	-7.48%	45,694
19/08/26	$3.210	-0.93%	76,126
18/08/26	$3.240	+2.53%	22,063
17/08/26	$3.160	-3.66%	81,257
14/08/26	$3.280	-5.75%	41,008

Delayed Quote Nasdaq

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq 23:30:00 20/08/2026 +03			5-day change	1st Jan Change
2.970 ^USD	-7.48%		-14.66%	-56.52%

08-15	TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-18	TransCode Therapeutics, Inc. - Special Call

Market Cap	3.14M 2.69M 2.51M 2.3M 4.33M 301M 4.42M 29.79M 11.61M 151M 11.8M 11.55M 499M	P/E 2024	-0.07x	P/E 2025	-0.13x
Enterprise Value	-14.67M -12.56M -11.72M -10.75M -20.21M -1.4B -20.6M -139M -54.19M -703M -55.08M -53.88M -2.33B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	96.45%	Yield 2024 *	-	Yield 2025	-

08-15	TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-18	TransCode Therapeutics, Inc. - Special Call
06-03	TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a	MT
06-03	Transcode Therapeutics Completes Phase 1A Clinical Trial and Advances Ttx-Mc138 to Phase 2A Development	CI
05-27	TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 In Patients With ctDNA Positive Colorectal Cancer	CI
05-15	TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-01	TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal	MT
04-27	Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board	RE
04-27	TransCode Therapeutics, Inc. Appoints Anna Moore as Chair of Scientific Advisory Board	CI
04-15	TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	TransCode Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-06	TransCode Therapeutics, Inc. announced that it expects to receive $19.7 million in funding from Yorkville Advisors Global LP	CI
03-03	Transcode Therapeutics, Inc. and Unleash Immuno Oncolytics, Inc. Secure Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement	CI

14/10/25	Transcode Therapeutics completes phase 1a trial with TTX-MC138 in metastatic disease at ESMO - SEC filing	RE
15/11/22	HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating	MT
07/06/22	HC Wainwright Starts TransCode Therapeutics at Buy With $10 Price Target	MT

TransCode Therapeutics, Inc. Stock

Stocks

RNAZ

US89357L5012

Biotechnology & Medical Research

Valuation: TransCode Therapeutics, Inc.

Chart: TransCode Therapeutics, Inc.

Latest news : TransCode Therapeutics, Inc.

Last Transcript: TransCode Therapeutics, Inc.

Analysts' recommendations: TransCode Therapeutics, Inc.

Press Releases: TransCode Therapeutics, Inc.

News in other languages: TransCode Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: TransCode Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

08-07	Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV	AQ
03-03	TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients	PR
02-23	TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development	PR
02-05	TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138	PR
01-06	TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma	PR

1 day	-7.48%
1 week	-14.66%
Current month	-34.87%
1 month	-65.98%
3 months	-51.39%
6 months	-69.35%
Current year	-56.52%

1 week	2.87	3.5
1 month	2.87	7.97
Current year	2.87	12.6
1 year	2.87	20.99
3 years	2.87	118,271.9
5 years	2.87	3,901,981.08
10 years	2.87	5,174,452.99

Manager	Title	Age	Since
Philippe Calais CEO	Chief Executive Officer	67	06/10/2025
Zdravka Medarova CTO	Chief Tech/Sci/R&D Officer	52	01/10/2021
Thomas Fitzgerald CEO	Chief Executive Officer	75	13/01/2024

Director	Title	Age	Since
Thomas Fitzgerald BRD	Director/Board Member	75	01/07/2018
Philippe Calais CHM	Chairman	67	18/02/2021
Erik Manting BRD	Director/Board Member	54	20/12/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/27/26 A	CK LIFE SCIENCES INTERNATIONAL (HOLDINGS), INC.	Other	Company	300,040	1.7722%
6/14/24 A	Magda Marquet	Free	Director	70,000	1.0654%
6/14/24 A	Erik Manting	Free	Director	70,000	1.0654%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSCODE THERAPEUTICS, INC.	-7.48%	-14.66%	-70.68%	-100.00%	3.14M
WUXI APPTEC CO., LTD.	+2.38%	+3.43%	+82.88%	+115.89%	73.96B
ARGENX SE	+0.87%	+17.34%	+57.17%	+97.28%	64.66B
INSMED INCORPORATED	-4.27%	-0.99%	-3.38%	+475.61%	27.32B
BIONTECH SE	-1.97%	+20.38%	-0.37%	+0.48%	27.86B
WUXI BIOLOGICS (CAYMAN) INC.	+2.44%	+12.54%	+62.20%	+27.64%	25.97B
GENMAB A/S	-0.51%	+5.73%	+38.71%	-12.79%	19.98B
PHARMAESSENTIA CORPORATION	-1.79%	-4.84%	+239.54%	+414.48%	17.84B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.47%	+2.98%	+18.11%	+530.59%	16.24B
EXELIXIS, INC.	-1.29%	+6.09%	+41.81%	+154.45%	13.3B
Average	-1.12%	+4.10%	+46.60%	+170.36%	28.71B
Weighted average by Cap.	+0.25%	+8.21%	+60.03%	+161.59%

	2024	2025
Net sales	-	-
Net income	-16.75M -14.35M -13.38M -12.28M -23.08M -1.6B -23.53M -159M -61.9M -803M -62.91M -61.54M -2.66B	-34.66M -29.68M -27.69M -25.41M -47.74M -3.32B -48.68M -328M -128M -1.66B -130M -127M -5.5B
Net Debt	-5.77M -4.94M -4.61M -4.23M -7.95M -552M -8.11M -54.71M -21.33M -277M -21.68M -21.2M -916M	-17.81M -15.25M -14.23M -13.06M -24.54M -1.7B -25.02M -169M -65.81M -854M -66.89M -65.43M -2.83B